Brokerages Set $41.33 Price Target for Opiant Pharmaceuticals Inc (NASDAQ:OPNT)

Opiant Pharmaceuticals Inc (NASDAQ:OPNT) has earned an average broker rating score of 1.00 (Strong Buy) from the two brokers that cover the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy recommendation.

Brokers have set a 12-month consensus target price of $41.33 for the company and are anticipating that the company will post ($0.47) earnings per share for the current quarter, according to Zacks. Zacks has also given Opiant Pharmaceuticals an industry rank of 87 out of 256 based on the ratings given to related companies.

OPNT has been the topic of a number of recent research reports. ValuEngine cut Universal Electronics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, June 6th. Northland Securities initiated coverage on Opiant Pharmaceuticals in a research note on Wednesday, May 29th. They issued an “outperform” rating and a $42.00 target price on the stock.

Shares of Opiant Pharmaceuticals stock traded down $0.15 on Friday, reaching $13.10. 13,183 shares of the company’s stock were exchanged, compared to its average volume of 15,264. The firm has a market cap of $51.48 million, a P/E ratio of -1.85 and a beta of 0.44. Opiant Pharmaceuticals has a 52 week low of $9.98 and a 52 week high of $29.55. The business has a 50-day moving average price of $13.05.

Opiant Pharmaceuticals (NASDAQ:OPNT) last posted its quarterly earnings results on Thursday, May 9th. The technology company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $0.44. Opiant Pharmaceuticals had a negative net margin of 30.98% and a negative return on equity of 32.67%. The business had revenue of $5.44 million during the quarter, compared to the consensus estimate of $1.90 million. On average, analysts expect that Opiant Pharmaceuticals will post 0.4 earnings per share for the current year.

In other news, insider Phil Skolnick sold 10,000 shares of the stock in a transaction on Tuesday, June 4th. The stock was sold at an average price of $11.71, for a total value of $117,100.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Over the last quarter, insiders sold 30,000 shares of company stock worth $362,900. Insiders own 30.88% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in OPNT. Northern Trust Corp raised its stake in Opiant Pharmaceuticals by 3.5% in the fourth quarter. Northern Trust Corp now owns 41,803 shares of the technology company’s stock valued at $604,000 after buying an additional 1,398 shares in the last quarter. Advisor Group Inc. raised its stake in shares of Opiant Pharmaceuticals by 57.2% in the 4th quarter. Advisor Group Inc. now owns 4,700 shares of the technology company’s stock valued at $69,000 after purchasing an additional 1,710 shares in the last quarter. Spark Investment Management LLC raised its stake in shares of Opiant Pharmaceuticals by 17.6% in the 1st quarter. Spark Investment Management LLC now owns 15,100 shares of the technology company’s stock valued at $198,000 after purchasing an additional 2,265 shares in the last quarter. BlackRock Inc. raised its stake in shares of Opiant Pharmaceuticals by 44.0% in the 4th quarter. BlackRock Inc. now owns 10,259 shares of the technology company’s stock valued at $149,000 after purchasing an additional 3,137 shares in the last quarter. Finally, Granite Investment Partners LLC acquired a new stake in shares of Opiant Pharmaceuticals in the 1st quarter valued at about $356,000. Institutional investors and hedge funds own 20.06% of the company’s stock.

Opiant Pharmaceuticals Company Profile

Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine.

Further Reading: Hedge Funds – Risk or Reward?

Get a free copy of the Zacks research report on Opiant Pharmaceuticals (OPNT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.